Clinical trial
A Multicenter, Open-Label, Randomised Trial to Compare the Efficacy and Safety of NovoLog Mix 70/30 BID in Combination With Metformin and Pioglitazone to Metformin and Pioglitazone Alone in Insulin Naïve Subjects With Type 2 Diabetes
NCT00097279 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Open-Label, Randomised Trial to Compare the Efficacy and Safety of NovoLog Mix 70/30 BID in Combination With Metformin and Pioglitazone to Metformin and Pioglitazone Alone in Insulin Naïve Subjects With Type 2 Diabetes
- Lead sponsor
- Novo Nordisk A/S
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- August 31, 2004
- Completion date
- August 31, 2005
- Enrollment
- 230 (actual)
- Sites
- 73
Conditions
As the registry lists them; a condition with its own page is linked.
diabetes, diabetes mellitus, type 2